Grifols, S.A. (GIFLF)
| Previous close | 0.00 |
| Open | 10.59 |
| Bid | 9.53 x 40000 |
| Ask | 10.48 x 46000 |
| Day's range | 9.65 - 10.68 |
| 52-week range | 7.46 - 15.80 |
| Volume | |
| Avg. volume | 500 |
| Market cap | 6.241B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 95.10 |
| EPS (TTM) | 0.10 |
| Earnings date | 30 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 03 June 2021 |
| 1y target est | N/A |
Simply Wall St.Three Stocks Estimated To Be Trading With Intrinsic Discounts Between 35.9% And 49.7%
As global markets exhibit mixed signals with the S&P 500 reaching record highs amid cooling labor markets and easing inflation pressures, investors are navigating a complex landscape. In such an environment, identifying stocks that are trading below their intrinsic value could present opportunities for discerning investors looking to potentially enhance their portfolios.
BloombergGrifols Says Founding Family, Brookfield Weigh Takeover Bid
(Bloomberg) -- Grifols SA said that its founding family and asset manager Brookfield have made an approach to buy and delist it, after the pharmaceutical producer lost billions in market value amid a short-seller attack. The shares jumped the most in four months.Most Read from BloombergMicrosoft Orders China Staff to Use iPhones for Work and Drop AndroidBoeing to Plead Guilty to Fraud for Violating Deal Over 737 Max CrashesBiden Narrows Gap With Trump in Swing States Despite Debate LossMorgan St
GlobeNewswireGrifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols’ strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other prote
